top of page
gradientForSurfBreak.png

Item List

PR Newswire
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

Invitae ( NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's Ciitizen platform were utilized as natural history data to support the submission of Praxis' Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE). Praxis announced earlier this month that the U.S. Food and Drug Administration (FDA) cleared the IND application for the initial dose cohort for the PRAX-222 EMBRAVE clinical study.

Recent Posts

Portfolio Company

Carlsmed.png

Regard and Kettering Health Hamilton Partner to Streamline EHR Navigation ...

PR Newswire

Portfolio Company

Carlsmed.png

Elektra Health Adds $3.3M in Seed Funding to Grow Its Platform for Evidence-base ...

FemTech Insider

Portfolio Company

Carlsmed.png

DeepScribe Launches New and Innovative Trust and Safety Suite for its Ambient AI ...

AIThority

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page